Uterine Fibroids Market Spotlight, 2026 – Repros Therapeutics has the Highest Number of Completed Clinical Trials

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Uterine Fibroids” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Uterine Fibroids market,
comprising key marketed and pipeline drugs, clinical trials, recent
events and analyst opinion, upcoming events, probability of success,
regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals.

Key Takeaways

• The report estimates that in 2017, there were approximately 92.2
  million prevalent cases of uterine fibroids worldwide in females aged
  15 years and over, and forecasts that number to increase to 102.7
  million prevalent cases by 2026.
• Lupron (leuprolide acetate), a gonadotropin-releasing hormone agonist,
  is the only approved drug for uterine fibroids. This drug is
  administered via the subcutaneous route.
• The majority of industry-sponsored drugs in active clinical
  development for uterine fibroids are in Phase III. Therapies in
  mid-to-late-stage development for uterine fibroids focus on targets
  such as the progesterone receptor, gonadotropin-releasing hormone
  receptor, and collagen. The majority of pipeline drugs are
  administered via the oral route, with one product being available in
  subcutaneous formulation.
• High-impact upcoming events for drugs in the uterine fibroids space
  comprise topline Phase III trial results for OBE2109 and relugolix,
  and an expected meeting with the FDA for ulipristal acetate.
• The overall likelihood of approval of a Phase I gynecology asset is
  13.1%, and the average probability a drug advances from Phase III is
  62.5%. Drugs, on average, take 11.1 years from Phase I to approval,
  compared to 12.0 years in the overall obstetrics/gynecology space.
• There have been 12 licensing and asset acquisition deals involving
  uterine fibroids drugs during 2013-18. The clinical trials
  distribution across Phase I-IV indicates that the majority of trials
  for uterine fibroids have been in the early and mid-phases of
  development, with 62% of trials in Phase I-II, and 38% in Phase III-IV.
• The US has a substantial lead in the number of uterine fibroids
  clinical trials globally. Poland and the UK lead the major EU markets,
  while Japan has the top spot in Asia.
• Clinical trial activity in the uterine fibroids space is dominated by
  completed trials. Repros Therapeutics has the highest number of
  completed clinical trials for uterine fibroids, with 17 trials.
• Repros Therapeutics leads industry sponsors with the highest number of
  clinical trials for uterine fibroids, followed by Takeda.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Surgery

Medical agents

EPIDEMIOLOGY

MARKETED DRUGS

Approvals by country

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Orilissa for Uterine Fibroids (August 22, 2018)

Ulipristal Acetate for Uterine Fibroids (August 21, 2018)

Ulipristal Acetate for Uterine Fibroids (May 18, 2018)

Orilissa for Uterine Fibroids (March 13, 2018)

Orilissa for Uterine Fibroids (February 21, 2018)

Ulipristal Acetate for Uterine Fibroids (February 9, 2018)

Vilaprisan for Uterine Fibroids (October 20, 2017)

Relugolix for Uterine Fibroids (October 2, 2017)

Proellex (Oral) for Uterine Fibroids (July 17, 2017)

Relugolix for Uterine Fibroids (May 7, 2017)

Ulipristal Acetate for Uterine Fibroids (January 17, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Allergan’s Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection

Esmya Review Held Back Gedeon Richter in First Half

Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

EMA Panel Finalises Safety Probe Into Richter’s Fibroid Drug Esmya

Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over
Liver Concerns

Ultrasonic Aspirator Guidance Requires Warning On Uterine Use

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Takeda Offloads Selected Japan Relugolix Rights

Allergan To Buy Repros And Stalled Uterine Fibroid Candidate

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/jfmydo

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health